Protara Therapeutics, Inc.

NasdaqGM:TARA Stock Report

Market Cap: US$32.6m

Protara Therapeutics Future Growth

Future criteria checks 0/6

Protara Therapeutics is forecast to grow earnings and revenue by 29.7% and 56.9% per annum respectively while EPS is expected to grow by 28% per annum.

Key information

29.7%

Earnings growth rate

28.0%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate56.9%
Future return on equityn/a
Analyst coverage

Low

Last updated09 Apr 2024

Recent future growth updates

Recent updates

Protara: A Bombed Out Biotech With A Very Positive Skew

Feb 22

Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Dec 16
Here's Why We're Watching Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

Apr 22
We Think Protara Therapeutics (NASDAQ:TARA) Can Afford To Drive Business Growth

The Prognosis For Protara Therapeutics

Oct 13

Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Sep 12
Here's Why We're Not Too Worried About Protara Therapeutics' (NASDAQ:TARA) Cash Burn Situation

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Mar 21
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Dec 06
Is Protara Therapeutics (NASDAQ:TARA) In A Good Position To Deliver On Growth Plans?

Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Aug 17
Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?

Earnings and Revenue Growth Forecasts

NasdaqGM:TARA - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202675-39-43N/A4
12/31/20259-62-78N/A4
12/31/2024N/A-52-55N/A5
12/31/2023N/A-40-38-38N/A
9/30/2023N/A-69-34-34N/A
6/30/2023N/A-67-33-33N/A
3/31/2023N/A-64-28-28N/A
12/31/2022N/A-66-27-26N/A
9/30/2022N/A-37-28-28N/A
6/30/2022N/A-40-29-29N/A
3/31/2022N/A-45-34-34N/A
12/31/2021N/A-47-35-35N/A
9/30/2021N/A-46-35-34N/A
6/30/2021N/A-43-33-32N/A
3/31/2021N/A-37-29-28N/A
12/31/2020N/A-34-24-23N/A
9/30/2020N/A-28-18-18N/A
6/30/2020N/A-22-16-15N/A
3/31/2020N/A-16-11-11N/A
12/31/2019N/A-8-5-5N/A
9/30/2019N/A-7-5-5N/A
12/31/2018N/A-4-3-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TARA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TARA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TARA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TARA is forecast to have no revenue next year.

High Growth Revenue: TARA is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TARA's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.